The European Organisation for Research and Treatment of Cancer (EORTC) and the Syreon Research Institute are delighted to announce the official start of LEGATO, a pragmatic phase III clinical trial focusing on recurrent Glioblastoma.

This is the first official trial looking into the potential benefits of chemo-irradiation compared to chemotherapy alone to improve disease control and survival in patients burdened by glioblastoma, which is by far the most common and aggressive malignant primary brain tumour in the adult population.

The study may lead to improved patient survival and quality of life but also improve health system sustainability. It may provide new insights in the treatment of this cancer and deeply change, worldwide, clinical practice for recurrent Glioblastoma.

The LEGATO project will run in 11 countries in Europe, including Austria, the Czech Republic, Denmark, France, Germany, Italy, the Netherlands, Norway, Switzerland, Spain, and Belgium. The study aims to recruit 411 patients from 43 sites.

Read the full article here: https://www.eortc.org/blog/2023/10/04/legato-official-start/